Clinical Trial Update: Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating canakinumab for acute gouty arthritis in patients with chronic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Gouty Arthritis | Phase 3 | Status: WITHDRAWN